Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

XERS

Xeris Biopharma Holdings Inc

Apr 10 • 04:00PM ET

5.85

-0.16 -2.66 %

Healthcare • Biotechnology • USA • NASD

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: VTI IWM VXF IWO XPH SCHA VTWO VHT IHE FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	7.16%	Shs Outstand	166.22M	Perf Week	-3.15%
Market Cap	1.01B	Forward P/E	16.65	EPS next Y	0.35	Insider Trans	-2.56%	Shs Float	160.09M	Perf Month	2.09%
Enterprise Value	1.16B	PEG	-	EPS next Q	0.00	Inst Own	58.74%	Short Float	10.25%	Perf Quarter	-28.04%
Income	0.55M	P/S	3.46	EPS this Y	3641.81%	Inst Trans	2.29%	Short Ratio	8.87	Perf Half Y	-28.66%
Sales	291.85M	P/B	71.03	EPS next Y	192.86%	ROA	0.15%	Short Interest	16.41M	Perf YTD	-25.48%
Book/sh	0.08	P/C	9.08	EPS next 5Y	-	ROE	-	52W High	10.08 -41.96%	Perf Year	48.10%
Cash/sh	0.64	P/FCF	36.12	EPS past 3/5Y	- -	ROIC	0.21%	52W Low	3.81 53.75%	Perf 3Y	201.55%
Dividend Est.	-	EV/EBITDA	30.75	Sales past 3/5Y	38.33% 70.20%	Gross Margin	81.70%	Volatility	4.40% 4.58%	Perf 5Y	38.30%
Dividend TTM	-	EV/Sales	3.96	EPS Y/Y TTM	99.47%	Oper. Margin	8.53%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.57	Sales Y/Y TTM	43.72%	Profit Margin	0.19%	RSI (14)	48.79	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	279.30%	SMA20	3.21%	Beta	0.82	Target Price	11.14
Payout	0.00%	Debt/Eq	18.85	Sales Q/Q	42.78%	SMA50	-5.96%	Rel Volume	0.51	Prev Close	6.01
Employees	435	LT Debt/Eq	18.40	Earnings	Mar 02 BMO	SMA200	-16.06%	Avg Volume	1.85M	Price	5.85
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	191.26% 4.39%	Trades		Volume	942,136	Change	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$9
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Apr-03-26 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-02-26 04:01PM	Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:33PM	Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
10:37AM	Xeris Biopharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:06AM	Loading…
08:06AM	Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:13AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance (Business Wire)
Feb-27-26 12:29PM	Why Are Shares Of Xeris Biopharma Falling Friday? (Benzinga) -9.20%
Feb-26-26 05:55PM	Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit (Business Wire)
12:15PM	BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:15AM	Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics (Zacks)
05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-17-26 07:30AM	Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 (Business Wire)
Jan-08-26 07:00AM	Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue (Business Wire) +12.76%
04:15PM	Loading…
Jan-02-26 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.37%
Dec-31-25 07:09PM	Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday (Motley Fool) +7.39%
Dec-18-25 01:13PM	Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory (Insider Monkey)
Dec-01-25 07:00AM	Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application (Business Wire)
Nov-06-25 09:30AM	Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -21.88%
08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
07:00AM	Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 (Business Wire)
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Loading…
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hecht Beth	See Remarks	Apr 01 '26	Sale	5.99	16,667	99,859	1,209,840	Apr 03 05:45 PM
Brady James Aloysius	Director	Mar 30 '26	Sale	5.54	10,834	60,036	89,166	Apr 01 05:54 PM
JAMES BRADY	Director	Mar 30 '26	Proposed Sale	5.40	10,834	58,504		Mar 30 05:31 PM
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16 06:11 PM
Pieper Steven	See Remarks	Mar 05 '26	Option Exercise	4.71	41,927	197,308	1,408,940	Mar 05 07:18 PM
Hecht Beth	See Remarks	Mar 02 '26	Sale	6.25	16,667	104,086	1,226,507	Mar 04 05:28 PM
BETH HECHT	Officer	Mar 02 '26	Proposed Sale	6.12	66,668	408,008		Mar 02 04:36 PM
Hecht Beth	See Remarks	Feb 02 '26	Sale	7.45	16,667	124,147	1,243,174	Feb 02 06:11 PM
McCulloch Kevin	See Remarks	Jan 08 '26	Sale	8.00	15,000	120,000	1,685,426	Jan 09 05:34 PM
KEVIN MCCULLOCH	Officer	Jan 08 '26	Proposed Sale	7.21	60,000	432,600		Jan 08 04:22 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Option Exercise	1.63	92,301	149,998	2,797,647	Jan 06 06:14 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Sale	7.08	24,907	176,257	2,705,346	Jan 06 06:14 PM
Hecht Beth	See Remarks	Jan 02 '26	Sale	7.43	16,667	123,776	1,308,103	Jan 05 06:01 PM
JOHN H JOHNSON	Director	Dec 19 '25	Proposed Sale	7.22	135,402	977,034		Dec 19 06:15 PM
JOHNSON JOHN	Director	Dec 19 '25	Sale	7.22	135,400	977,019	698,083	Dec 19 05:17 PM
BORMANN-KENNEDY BARBARA-JEAN A	Director	Dec 12 '25	Sale	7.09	15,000	106,414	142,500	Dec 15 05:24 PM
BARBARA-JEAN A BORMANN-KENNEDY	Director	Dec 12 '25	Proposed Sale	7.01	15,000	105,150		Dec 12 04:20 PM
Hecht Beth	See Remarks	Dec 01 '25	Sale	7.01	16,667	116,781	1,320,176	Dec 02 05:14 PM
Shannon John Patrick Jr	See Remarks	Nov 14 '25	Option Exercise	1.55	87,100	135,005	2,730,253	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Option Exercise	1.55	8,970	13,904	2,666,395	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Sale	7.46	23,242	173,402	2,643,153	Nov 17 05:58 PM
Hecht Beth	See Remarks	Nov 11 '25	Sale	7.40	16,667	123,296	1,336,843	Nov 13 06:59 PM
JOHN SHANNON	Director	Nov 13 '25	Proposed Sale	7.59	48,149	365,451		Nov 13 04:25 PM
BETH HECHT	Officer	Nov 11 '25	Proposed Sale	7.72	66,668	514,677		Nov 12 07:02 AM
PERSKY MARLA	Director	Sep 11 '25	Sale	7.72	15,500	119,610	142,000	Sep 12 05:09 PM
MARLA PERSKY	Director	Sep 11 '25	Proposed Sale	7.81	15,500	121,055		Sep 11 04:24 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Option Exercise	6.66	47,040	313,286	261,420	Aug 29 05:21 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Sale	7.92	42,232	334,515	219,188	Aug 29 05:21 PM
JEFFREY SHERMAN	Director	Aug 28 '25	Proposed Sale	7.92	42,232	334,511		Aug 28 04:09 PM
JOHNSON JOHN	Director	Aug 13 '25	Sale	7.32	107,500	786,459	833,483	Aug 15 04:57 PM
HALKUFF DAWN	Director	Aug 12 '25	Sale	7.28	42,500	309,226	115,000	Aug 13 04:47 PM
JOHN H JOHNSON	Director	Aug 13 '25	Proposed Sale	7.32	107,500	786,452		Aug 13 04:08 PM
DAWN HALKUFF	Director	Aug 12 '25	Proposed Sale	7.28	42,500	309,226		Aug 12 04:23 PM
McCulloch Kevin	See Remarks	Jun 13 '25	Buy	4.38	25,000	109,475	1,708,585	Jun 16 04:26 PM
Fairley Ricki Louise	Director	May 09 '25	Proposed Sale	4.90	56,667	277,668		May 09 05:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XERS

Xeris Biopharma Holdings Inc

Upgrade your Finviz experience